# electroCore, Inc.: financial statements, quarterly ECOR · Nasdaq · CIK 1560258 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/ecor.md) · [Financials](/companies/ecor/financials.md) · [Filings](/companies/ecor/filings.md) · [Insiders](/companies/ecor/insiders.md) Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ecor/financials.md?period=annual). ## Income statement | Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [4.5](/filings/0001213900-24-097489.md) | [5.2 d](/filings/0001213900-25-023259.md) | [5.4](/filings/0001641172-25-009043.md) | [6.1](/filings/0001641172-25-022432.md) | [6.6](/filings/0001493152-25-020884.md) | [7.0 d](/filings/0001493152-26-011636.md) | [6.7](/filings/0001493152-26-021495.md) | [7.4](/filings/0001493152-26-036348.md) | [8.7](/filings/0001493152-25-020884.md) | [9.2 d](/filings/0001493152-26-011636.md) | [9.6](/filings/0001493152-26-021495.md) | [9.5](/filings/0001493152-26-036348.md) | | Cost of revenue | $m | [0.7](/filings/0001213900-24-097489.md) | [1.1 d](/filings/0001213900-25-023259.md) | [0.9](/filings/0001641172-25-009043.md) | [0.8](/filings/0001641172-25-022432.md) | [1.1](/filings/0001493152-25-020884.md) | [1.0 d](/filings/0001493152-26-011636.md) | [1.0](/filings/0001493152-26-021495.md) | [0.9](/filings/0001493152-26-036348.md) | [1.2](/filings/0001493152-25-020884.md) | [1.1 d](/filings/0001493152-26-011636.md) | [1.2](/filings/0001493152-26-021495.md) | [1.3](/filings/0001493152-26-036348.md) | | Gross profit | $m | [3.8](/filings/0001213900-24-097489.md) | [4.1 d](/filings/0001213900-25-023259.md) | [4.6](/filings/0001641172-25-009043.md) | [5.3](/filings/0001641172-25-022432.md) | [5.5](/filings/0001493152-25-020884.md) | [6.1 d](/filings/0001493152-26-011636.md) | [5.7](/filings/0001493152-26-021495.md) | [6.4](/filings/0001493152-26-036348.md) | [7.5](/filings/0001493152-25-020884.md) | [8.2 d](/filings/0001493152-26-011636.md) | [8.4](/filings/0001493152-26-021495.md) | [8.2](/filings/0001493152-26-036348.md) | | Research and development | $m | [1.2](/filings/0001213900-24-097489.md) | [1.1 d](/filings/0001213900-25-023259.md) | [0.4](/filings/0001641172-25-009043.md) | [0.6](/filings/0001641172-25-022432.md) | [0.5](/filings/0001493152-25-020884.md) | [0.8 d](/filings/0001213900-25-023259.md) | [0.6](/filings/0001641172-25-009043.md) | [0.5](/filings/0001641172-25-022432.md) | [0.7](/filings/0001493152-25-020884.md) | not reported | not reported | not reported | | Selling, general and administrative | $m | [6.7](/filings/0001213900-24-097489.md) | [6.9 d](/filings/0001213900-25-023259.md) | [8.0](/filings/0001641172-25-009043.md) | [7.3](/filings/0001641172-25-022432.md) | [7.6](/filings/0001493152-25-020884.md) | [8.3 d](/filings/0001493152-26-011636.md) | [8.9](/filings/0001493152-26-021495.md) | [9.4](/filings/0001493152-26-036348.md) | [9.7](/filings/0001493152-25-020884.md) | [10.2 d](/filings/0001493152-26-011636.md) | [12.9](/filings/0001493152-26-021495.md) | [10.1](/filings/0001493152-26-036348.md) | | Operating income | $m | [(4.1)](/filings/0001213900-24-097489.md) | [(4.0) d](/filings/0001213900-25-023259.md) | [(3.8)](/filings/0001641172-25-009043.md) | [(2.6)](/filings/0001641172-25-022432.md) | [(2.7)](/filings/0001493152-25-020884.md) | [(3.1) d](/filings/0001493152-26-011636.md) | [(3.8)](/filings/0001493152-26-021495.md) | [(3.5)](/filings/0001493152-26-036348.md) | [(2.9)](/filings/0001493152-25-020884.md) | [(2.9) d](/filings/0001493152-26-011636.md) | [(5.3)](/filings/0001493152-26-021495.md) | [(2.8)](/filings/0001493152-26-036348.md) | | Interest expense | $m | not reported | not reported | [0.0](/filings/0001641172-25-009043.md) | [0.0](/filings/0001641172-25-022432.md) | [0.0](/filings/0001493152-25-020884.md) | [0.0 d](/filings/0001493152-26-011636.md) | [0.0](/filings/0001493152-26-021495.md) | [0.0](/filings/0001493152-26-036348.md) | [0.0](/filings/0001493152-25-020884.md) | [0.0 d](/filings/0001493152-26-011636.md) | [0.0](/filings/0001493152-26-021495.md) | [0.0](/filings/0001493152-26-036348.md) | | Income tax | $m | [0.0 d](/filings/0001213900-24-097489.md) | [0.0 d](/filings/0001213900-25-023259.md) | [(0.1)](/filings/0001641172-25-009043.md) | [0.0 d](/filings/0001641172-25-022432.md) | [0.0 d](/filings/0001493152-25-020884.md) | [0.0 d](/filings/0001493152-26-011636.md) | [(0.0)](/filings/0001493152-26-021495.md) | [0.0 d](/filings/0001493152-26-036348.md) | [0.0 d](/filings/0001493152-25-020884.md) | [0.1 d](/filings/0001493152-26-011636.md) | [(0.3)](/filings/0001493152-26-021495.md) | [0.0 d](/filings/0001493152-26-036348.md) | | Net income | $m | [(4.0)](/filings/0001213900-24-097489.md) | [(4.0) d](/filings/0001213900-25-023259.md) | [(3.5)](/filings/0001493152-25-020884.md) | [(2.7)](/filings/0001493152-25-020884.md) | [(2.5)](/filings/0001493152-25-020884.md) | [(3.2) d](/filings/0001493152-26-011636.md) | [(3.9)](/filings/0001493152-26-036348.md) | [(3.7)](/filings/0001493152-26-036348.md) | [(3.4)](/filings/0001493152-25-020884.md) | [(3.0) d](/filings/0001493152-26-011636.md) | [(5.3)](/filings/0001493152-26-036348.md) | [(3.1)](/filings/0001493152-26-036348.md) | | Diluted EPS | $ per share | [(0.68)](/filings/0001213900-24-097489.md) | not reported | [(0.53)](/filings/0001641172-25-009043.md) | [(0.38)](/filings/0001641172-25-022432.md) | [(0.31)](/filings/0001493152-25-020884.md) | not reported | [(0.47)](/filings/0001493152-26-021495.md) | [(0.44)](/filings/0001493152-26-036348.md) | [(0.40)](/filings/0001493152-25-020884.md) | not reported | [(0.59)](/filings/0001493152-26-021495.md) | [(0.33)](/filings/0001493152-26-036348.md) | | Basic EPS | $ per share | [(0.68)](/filings/0001213900-24-097489.md) | not reported | [(0.53)](/filings/0001641172-25-009043.md) | [(0.38)](/filings/0001641172-25-022432.md) | [(0.31)](/filings/0001493152-25-020884.md) | not reported | [(0.47)](/filings/0001493152-26-021495.md) | [(0.44)](/filings/0001493152-26-036348.md) | [(0.40)](/filings/0001493152-25-020884.md) | not reported | [(0.59)](/filings/0001493152-26-021495.md) | [(0.33)](/filings/0001493152-26-036348.md) | - Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax - Cost of revenue: us-gaap:CostOfGoodsAndServicesSold - Gross profit: us-gaap:GrossProfit - Research and development: us-gaap:ResearchAndDevelopmentExpense - Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense - Operating income: us-gaap:OperatingIncomeLoss - Interest expense: us-gaap:InterestExpense - Income tax: us-gaap:IncomeTaxExpenseBenefit - Net income: us-gaap:NetIncomeLoss - Diluted EPS: us-gaap:EarningsPerShareDiluted - Basic EPS: us-gaap:EarningsPerShareBasic ## Balance sheet | Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash and equivalents | $m | [13.5](/filings/0001213900-24-097489.md) | [10.3](/filings/0001213900-25-023259.md) | [7.8](/filings/0001213900-24-040888.md) | [10.3](/filings/0001213900-24-066131.md) | [4.9](/filings/0001213900-24-097489.md) | [3.7](/filings/0001493152-26-011636.md) | [3.8](/filings/0001641172-25-009043.md) | [3.4](/filings/0001641172-25-022432.md) | [7.9](/filings/0001493152-25-020884.md) | [7.0](/filings/0001493152-26-036348.md) | [4.9](/filings/0001493152-26-021495.md) | [8.5](/filings/0001493152-26-036348.md) | | Current assets | $m | [17.8](/filings/0001213900-23-084764.md) | [14.3](/filings/0001213900-25-023259.md) | [11.7](/filings/0001213900-24-040888.md) | [18.0](/filings/0001213900-24-066131.md) | [16.8](/filings/0001213900-24-097489.md) | [16.3](/filings/0001493152-26-011636.md) | [12.0](/filings/0001641172-25-009043.md) | [10.6](/filings/0001641172-25-022432.md) | [17.3](/filings/0001493152-25-020884.md) | [15.7](/filings/0001493152-26-036348.md) | [12.5](/filings/0001493152-26-021495.md) | [14.1](/filings/0001493152-26-036348.md) | | Total assets | $m | [20.1](/filings/0001213900-23-084764.md) | [16.1](/filings/0001213900-25-023259.md) | [13.9](/filings/0001213900-24-040888.md) | [22.4](/filings/0001213900-24-066131.md) | [21.0](/filings/0001213900-24-097489.md) | [20.5](/filings/0001493152-26-011636.md) | [16.0](/filings/0001641172-25-009043.md) | [14.6](/filings/0001641172-25-022432.md) | [21.4](/filings/0001493152-25-020884.md) | [18.7](/filings/0001493152-26-036348.md) | [15.5](/filings/0001493152-26-021495.md) | [17.1](/filings/0001493152-26-036348.md) | | Current liabilities | $m | [8.5](/filings/0001213900-23-084764.md) | [8.1](/filings/0001213900-25-023259.md) | [7.8](/filings/0001213900-24-040888.md) | [7.3](/filings/0001213900-24-066131.md) | [7.9](/filings/0001213900-24-097489.md) | [9.2](/filings/0001493152-26-011636.md) | [7.9](/filings/0001641172-25-009043.md) | [9.6](/filings/0001641172-25-022432.md) | [12.1](/filings/0001493152-25-020884.md) | [11.3](/filings/0001493152-26-036348.md) | [12.3](/filings/0001493152-26-021495.md) | [11.7](/filings/0001493152-26-036348.md) | | Total liabilities | $m | [9.1](/filings/0001213900-23-084764.md) | [8.7](/filings/0001213900-25-023259.md) | [9.4](/filings/0001213900-24-040888.md) | [10.9](/filings/0001213900-24-066131.md) | [11.6](/filings/0001213900-24-097489.md) | [12.9](/filings/0001493152-26-011636.md) | [11.7](/filings/0001641172-25-009043.md) | [13.4](/filings/0001641172-25-022432.md) | [22.5](/filings/0001493152-25-020884.md) | [20.4](/filings/0001493152-26-036348.md) | [21.2](/filings/0001493152-26-021495.md) | [19.9](/filings/0001493152-26-036348.md) | | Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [6.5](/filings/0001493152-25-020884.md) | [6.6](/filings/0001493152-26-036348.md) | [6.4](/filings/0001493152-26-021495.md) | [5.8](/filings/0001493152-26-036348.md) | | Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.3](/filings/0001493152-26-021495.md) | [1.0](/filings/0001493152-26-036348.md) | | Shareholders' equity | $m | [11.0](/filings/0001213900-24-097489.md) | [7.4](/filings/0001493152-26-011636.md) | [4.5](/filings/0001493152-25-020884.md) | [11.5](/filings/0001493152-25-020884.md) | [9.5](/filings/0001493152-25-020884.md) | [7.5](/filings/0001493152-26-036348.md) | [4.4](/filings/0001493152-26-036348.md) | [1.1](/filings/0001493152-26-036348.md) | [(1.1)](/filings/0001493152-25-020884.md) | [(1.7)](/filings/0001493152-26-036348.md) | [(5.7)](/filings/0001493152-26-036348.md) | [(2.8)](/filings/0001493152-26-036348.md) | - Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue - Current assets: us-gaap:AssetsCurrent - Total assets: us-gaap:Assets - Current liabilities: us-gaap:LiabilitiesCurrent - Total liabilities: us-gaap:Liabilities - Long-term debt: us-gaap:LongTermDebtNoncurrent - Current portion of debt: not reported - Short-term borrowings: us-gaap:ShortTermBorrowings - Shareholders' equity: us-gaap:StockholdersEquity ## Cash flow | Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Operating cash flow | $k | [(2,373) d](/filings/0001213900-24-097489.md) | [(3,123) d](/filings/0001213900-25-023259.md) | [(2,558)](/filings/0001641172-25-009043.md) | [(1,772) d](/filings/0001641172-25-022432.md) | [(1,363) d](/filings/0001493152-25-020884.md) | [(1,255) d](/filings/0001493152-26-011636.md) | [(4,355)](/filings/0001493152-26-021495.md) | [(623) d](/filings/0001493152-26-036348.md) | [(1,669) d](/filings/0001493152-25-020884.md) | [(1,540) d](/filings/0001493152-26-011636.md) | [(3,008)](/filings/0001493152-26-021495.md) | [(3,518) d](/filings/0001493152-26-036348.md) | | Capital expenditure | $k | [74.0 d](/filings/0001213900-24-097489.md) | [41.0 d](/filings/0001213900-25-023259.md) | not reported | not reported | not reported | not reported | [37.0](/filings/0001493152-26-021495.md) | [25.0 d](/filings/0001493152-26-036348.md) | [4.0 d](/filings/0001493152-25-020884.md) | [0.0 d](/filings/0001493152-26-011636.md) | [2.0](/filings/0001493152-26-021495.md) | [4.0 d](/filings/0001493152-26-036348.md) | - Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities - Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment ## Shares | Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Diluted shares (weighted) | thousands of shares | [4,544](/filings/0001213900-23-084764.md) | [4,743](/filings/0001213900-24-040888.md) | [4,751](/filings/0001213900-24-066131.md) | [5,945](/filings/0001213900-24-097489.md) | [6.6](/filings/0001641172-25-009043.md) | [7.0](/filings/0001641172-25-022432.md) | [8.1](/filings/0001493152-25-020884.md) | [8.3](/filings/0001493152-26-021495.md) | [8.3](/filings/0001493152-26-036348.md) | [8.4](/filings/0001493152-25-020884.md) | [9.0](/filings/0001493152-26-021495.md) | [9.4](/filings/0001493152-26-036348.md) | - Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding Shares outstanding: 9,015,885 at 2026-07-31, from the cover of the [10-Q filed 2026-08-06](/filings/0001493152-26-036348.md) (dei:EntityCommonStockSharesOutstanding). Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:42 ET. No prices; not investment advice.